Protalix BioTherapeutics Inc (PLX)
1.18
0.00 (0.00%)
USD |
NYAM |
Apr 26, 09:44
Protalix BioTherapeutics Research and Development Expense (Quarterly): 3.102M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 3.102M |
| September 30, 2023 | 3.669M |
| June 30, 2023 | 4.475M |
| March 31, 2023 | 5.847M |
| December 31, 2022 | 5.617M |
| September 30, 2022 | 7.386M |
| June 30, 2022 | 7.579M |
| March 31, 2022 | 8.767M |
| December 31, 2021 | 7.641M |
| September 30, 2021 | 7.282M |
| June 30, 2021 | 7.689M |
| March 31, 2021 | 7.122M |
| December 31, 2020 | 10.95M |
| September 30, 2020 | 7.688M |
| June 30, 2020 | 9.186M |
| March 31, 2020 | 10.34M |
| December 31, 2019 | 9.595M |
| September 30, 2019 | 10.00M |
| June 30, 2019 | 13.32M |
| March 31, 2019 | 11.70M |
| December 31, 2018 | 9.575M |
| September 30, 2018 | 10.07M |
| June 30, 2018 | 7.241M |
| March 31, 2018 | 6.443M |
| December 31, 2017 | 8.99M |
| Date | Value |
|---|---|
| September 30, 2017 | 6.389M |
| June 30, 2017 | 8.826M |
| March 31, 2017 | 4.629M |
| December 31, 2016 | 5.708M |
| September 30, 2016 | 5.056M |
| June 30, 2016 | 7.819M |
| March 31, 2016 | 6.025M |
| December 31, 2015 | 6.407M |
| September 30, 2015 | 3.952M |
| June 30, 2015 | 4.694M |
| March 31, 2015 | 4.972M |
| December 31, 2014 | 5.09M |
| September 30, 2014 | 6.105M |
| June 30, 2014 | 4.962M |
| March 31, 2014 | 6.067M |
| December 31, 2013 | 8.594M |
| September 30, 2013 | 5.637M |
| June 30, 2013 | 6.458M |
| March 31, 2013 | 5.323M |
| December 31, 2012 | 6.627M |
| September 30, 2012 | 6.363M |
| June 30, 2012 | 8.855M |
| March 31, 2012 | 6.844M |
| December 31, 2011 | 7.535M |
| September 30, 2011 | 7.918M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
3.102M
Minimum
Dec 2023
13.32M
Maximum
Jun 2019
7.751M
Average
7.641M
Median
Dec 2021
Research and Development Expense (Quarterly) Benchmarks
| Agenus Inc | -- |
| InfuSystems Holdings Inc | -- |
| Corbus Pharmaceuticals Holdings Inc | 6.980M |
| AIM ImmunoTech Inc | 3.20M |
| Armata Pharmaceuticals Inc | 7.928M |